Premium
Response to a hepatitis b polypeptide vaccine in micelle form in a young adult population
Author(s) -
Blaine Hollinger F.,
Troisi Catherine,
Heiberg Dorothy,
Sanchez Yanuario,
Dreesman Gordon R.,
Meinick Joseph L.
Publication year - 1986
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890190305
Subject(s) - seroconversion , hbsag , immunogenicity , immunization , population , antibody , virology , antigen , hepatitis b vaccine , immunity , medicine , immunology , antibody response , hepatitis b virus , chemistry , immune system , virus , environmental health
Polypeptide micelles with relative molecular weights of 25,000 (p25) and 30,000 (gp30) daltons were prepared from native 22‐nm hepatitis B surface antigen (HBsAg) particles. This p25/gp30 complex was alum‐adsorbed, and three dosage levels (20 m̈g, 4 m̈g, and 0.8 m̈g) were administered at 0, 1, and 6 months to 51 human volunteers. Local and systemic reactions were clinically insignificant, and all vaccinees seroconverted, regardless of dose. As anticipated, antibody responses diminished as the dosage was reduced. Seroconversion rates and geometric mean antibody levels for the 20 m̈g dosage group were significantly better than those observed with a commercial vaccine and were comparable to those achieved after immunization with 40 m̈g of the intact 22‐nm particles used to prepare the polypeptides. By 2 weeks, an anti‐HBs response was elicited in 80% of the group receiving 20 m̈g of the polypeptide vaccine. This rapid response to immunization may be particularly beneficial for postexposure prophylaxis where the early development of immunity is advantageous.